Literature DB >> 6141562

Operational models of pharmacological agonism.

J W Black, P Leff.   

Abstract

The traditional receptor-stimulus model of agonism began with a description of drug action based on the law of mass action and has developed by a series of modifications, each accounting for new experimental evidence. By contrast, in this paper an approach to modelling agonism is taken that begins with the observation that experimental agonist-concentration effect, E/[A], curves are commonly hyperbolic and develops using the deduction that the relation between occupancy and effect must be hyperbolic if the law of mass action applies at the agonist-receptor level. The result is a general model that explicitly describes agonism by three parameters: an agonist-receptor dissociation constant, KA; the total receptor concentration, [R0]; and a parameter, KE, defining the transduction of agonist-receptor complex, AR, into pharmacological effect. The ratio, [R0]/KE, described here as the 'transducer ratio', tau, is a logical definition for the efficacy of an agonist in a system. The model may be extended to account for non-hyperbolic E/[A] curves with no loss of meaning. Analysis shows that an explicit formulation of the traditional receptor-stimulus model is one particular form of the general model but that it is not the simplest. An alternative model is proposed, representing the cognitive and transducer functions of a receptor, that describes agonist action with one fewer parameter than the traditional model. In addition, this model provides a chemical definition of intrinsic efficacy making this parameter experimentally accessible in principle. The alternative models are compared and contrasted with regard to their practical and conceptual utilities in experimental pharmacology.

Mesh:

Substances:

Year:  1983        PMID: 6141562     DOI: 10.1098/rspb.1983.0093

Source DB:  PubMed          Journal:  Proc R Soc Lond B Biol Sci        ISSN: 0950-1193


  360 in total

1.  Mechanism-based modeling of adaptive changes in the pharmacodynamics of midazolam in the kindling model of epilepsy.

Authors:  A Cleton; P H Van der Graaf; W Ghijsen; R Voskuyl; M Danhof
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

2.  Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens.

Authors:  A Christopoulos; P Coles; L Lay; M J Lew; J A Angus
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

3.  Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam.

Authors:  A Cleton; J Odman; P H Van der Graaf; W Ghijsen; R Voskuyl; M Danhof
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

4.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

5.  An analysis of glucocorticoid receptor-mediated gene expression in BEAS-2B human airway epithelial cells identifies distinct, ligand-directed, transcription profiles with implications for asthma therapeutics.

Authors:  T Joshi; M Johnson; R Newton; M Giembycz
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

6.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

7.  Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

8.  Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus.

Authors:  P B Osborne; B Chieng; M J Christie
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

9.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

Review 10.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.